EVAX Live signals | Maximize Profits with Getagraph.com

BUY 105706 min ago

@ $4.00

Issued: 13 Feb 2024 @ 15:29

Return: 4.50%

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections...

Stats
Today's Volume	24 736.00
Average Volume	95 606.00
Market Cap	21.80M
EPS	$0 ( 2023-12-18 )
Next earnings date	( $-0.550 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.520
ATR14	$0.0690 (1.72%)

Evaxion Biotech A/S Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evaxion Biotech A/S Financials

Annual	2023
Revenue:	$73 112.00
Gross Profit:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2023
Revenue:	$73 112.00
Gross Profit:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2022
Revenue:	$0
Gross Profit:	$-571 319 (0.00 %)
EPS:	$-9.80

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.514

Financial Reports:

No articles found.

Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.